Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D, Lowe J, Gajjar A, Zhao W, Broniscer A, Ellison DW, Grundy RG, Baker SJ.

J Clin Oncol. 2010 Jun 20;28(18):3061-8. doi: 10.1200/JCO.2009.26.7252. Epub 2010 May 17.

2.

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA.

Neuro Oncol. 2010 Jul;12(7):621-30. doi: 10.1093/neuonc/noq007. Epub 2010 Feb 14.

3.

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD.

Cancer Res. 2010 Jan 15;70(2):512-9. doi: 10.1158/0008-5472.CAN-09-1851. Epub 2010 Jan 12.

4.

Anaplasia in pilocytic astrocytoma predicts aggressive behavior.

Rodriguez FJ, Scheithauer BW, Burger PC, Jenkins S, Giannini C.

Am J Surg Pathol. 2010 Feb;34(2):147-60. doi: 10.1097/PAS.0b013e3181c75238.

PMID:
20061938
5.

Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.

Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF.

Acta Neuropathol. 2010 May;119(5):641-9. doi: 10.1007/s00401-009-0634-9. Epub 2010 Jan 1.

PMID:
20044755
6.

PTEN dosage is essential for neurofibroma development and malignant transformation.

Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, Wu H.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19479-84. doi: 10.1073/pnas.0910398106. Epub 2009 Oct 21.

7.

Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.

Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, Nagarajan R, Gutmann DH.

Neurology. 2009 Nov 10;73(19):1526-31. doi: 10.1212/WNL.0b013e3181c0664a. Epub 2009 Sep 30.

8.

Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours.

Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, Serre D, Hauser P, Garami M, Bognar L, Hanzely Z, Montes JL, Atkinson J, Farmer JP, Bouffet E, Hawkins C, Tabori U, Jabado N.

Br J Cancer. 2009 Aug 18;101(4):722-33. doi: 10.1038/sj.bjc.6605179. Epub 2009 Jul 14.

9.

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, Chaplin T, Carter RL, Gajjar A, Broniscer A, Young BD, Ellison DW, Sheer D.

J Pathol. 2009 Jun;218(2):172-81. doi: 10.1002/path.2558.

PMID:
19373855
10.

Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.

Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP.

Oncogene. 2009 May 21;28(20):2119-23. doi: 10.1038/onc.2009.73. Epub 2009 Apr 13.

11.

Histopathologic predictors of pilocytic astrocytoma event-free survival.

Tibbetts KM, Emnett RJ, Gao F, Perry A, Gutmann DH, Leonard JR.

Acta Neuropathol. 2009 Jun;117(6):657-65. doi: 10.1007/s00401-009-0506-3. Epub 2009 Mar 7.

PMID:
19271226
12.

Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes.

Rodriguez FJ, Giannini C, Asmann YW, Sharma MK, Perry A, Tibbetts KM, Jenkins RB, Scheithauer BW, Anant S, Jenkins S, Eberhart CG, Sarkaria JN, Gutmann DH.

J Neuropathol Exp Neurol. 2008 Dec;67(12):1194-204. doi: 10.1097/NEN.0b013e31818fbe1e.

13.

Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.

Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, Sutton LN, Storm PB, Shaikh TH, Biegel JA.

Brain Pathol. 2009 Jul;19(3):449-58. doi: 10.1111/j.1750-3639.2008.00225.x. Epub 2008 Oct 21. Erratum in: Brain Pathol. 2009 Jul;19(3):550.

14.

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Jones DT, Kocialkowski S, Liu L, Pearson DM, B├Ącklund LM, Ichimura K, Collins VP.

Cancer Res. 2008 Nov 1;68(21):8673-7. doi: 10.1158/0008-5472.CAN-08-2097.

15.

Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.

Rodriguez FJ, Scheithauer BW, Giannini C, Bryant SC, Jenkins RB.

Cancer. 2008 Nov 15;113(10):2779-89. doi: 10.1002/cncr.23899.

16.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Cancer Genome Atlas Research Network.

Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4. Erratum in: Nature. 2013 Feb 28;494(7438):506.

17.

Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma.

Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG.

J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87. doi: 10.1097/NEN.0b013e3181845622.

PMID:
18716556
18.

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P.

J Clin Invest. 2008 May;118(5):1739-49. doi: 10.1172/JCI33656.

19.

Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients.

Rodriguez FJ, Perry A, Gutmann DH, O'Neill BP, Leonard J, Bryant S, Giannini C.

J Neuropathol Exp Neurol. 2008 Mar;67(3):240-9. doi: 10.1097/NEN.0b013e318165eb75.

20.

Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.

Warrington NM, Woerner BM, Daginakatte GC, Dasgupta B, Perry A, Gutmann DH, Rubin JB.

Cancer Res. 2007 Sep 15;67(18):8588-95.

Supplemental Content

Support Center